Hexaminolevulinate

DRACPC ID  DRACPC0022

Active Ingredients   Hexaminolevulinate

Description  The hexyl ester of 5-aminolevulinic acid (ALA) with photodynamic properties. As a precursor of photoactive porphorins, hexyl 5-aminolevulinate induces the endogenous production of the photosensitizer protoporphyrin IX (PPIX) which accumulates selectively in tumor tissue. When exposed to specific wavelengths of light, PPIX is activated and, depending on the wavelength and/or intensity of light, either fluoresces, thereby allowing tumor imaging, or induces tumor cell apoptosis.

Synonyms  HAL; HexvixR; hexyl 5-aminolevulinate; Hexaminolevulinate

Type  Small Molecule

Disease  Bladder Carcinoma

Classification

  

Amino acid and derivative

Structure Information


Molecular Formula  C11H21NO3

Molecular Weight  215.29

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  hexyl 5-amino-4-oxopentanoate

InChI  InChI=1S/C11H21NO3/c1-2-3-4-5-8-15-11(14)7-6-10(13)9-12/h2-9,12H2,1H3

InChI_Key RYQOILLJDKPETL-UHFFFAOYSA-N

SMILES  O=C(OCCCCCC)CCC(CN)=O

External Codes


PubChem CID  6433083

DrugBank Accession Number  DB06261

NCI Thesaurus Code  C26654  

UNII  G7H20TKI67   GSRS

CAS  140898-97-1



Drug approval


Drug indication
    Hexaminolevulinate is indicated for use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy.

Drug Name Strength Dosage Form/Route Company Marketing Status Drug ID Approval year
Cysview Kit 100mg/vial For Solution; Intravesical Photocure Asa Prescription NDA: 022555 2010
Cysview 100mg/vial Powder For Solution; Intravesical Photocure Asa Prescription DIN: 02436639 2015

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00285701 Early Detection of Pre-malignant and Malignant Conditions in the Colon by Means of Fluorescence Endoscopy Using Local and Oral Sensitisation With Hexaminolevulinate (HAL) - a Dose Finding Study Colorectal Cancer Phase 1/2 Diagnostic
NCT01256424 A Randomized Phase II Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low/Moderate-grade Cervical Intraepithelial Neoplasia (CIN1 or 2) Cervical Intraepithelial Neoplasia Phase 2 Treatment
NCT00785694 Recurrence of Bladder Cancer After Transurethral Resection With Hexvix Bladder Cancer Phase 4 Diagnostic
NCT00412971 A Randomized, Comparative Phase III, 2-center Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer Bladder Cancer Phase 3 Diagnostic
NCT01303991 A Phase I Feasibility Study of Hexvix Photodynamic Therapy in Patients With Intermediate or High-risk Bladder Cancer Intermediate or High-risk Bladder Cancer Phase 1 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.